Scarica l'app Stockscreener
3.58
1.38%
-0.05
Dopo l'orario di chiusura:
3.70
0.12
+3.35%
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN
ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire
ProQR Announces Major Share Offering Agreement - TipRanks
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St
ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM
Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com
ProQR launches public offering to fund RNA therapy research - Investing.com India
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan
ProQR Therapeutics announces public offering of ordinary shares - MSN
ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance
RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data - Bloomberg
Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Best Momentum Stocks to Buy for October 2nd - Yahoo Finance
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - SETE News
What technical indicators reveal about PRQR stock - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK
ProQR Therapeutics NV (FRA:0PQ) Financial Strength : 3 (As of Jun. 2024) - GuruFocus.com
Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN) - Defense World
ProQR Therapeutics NV (FRA:0PQ) Enterprise Value : €86.81 Mil (As of Aug. 17, 2024) - GuruFocus.com
Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR: Q2 Earnings Snapshot - San Antonio Express-News
ProQR Therapeutics N.V. Financial Performance Review - TipRanks
ProQR Announces Second Quarter 2024 Operating and Financial Results - GlobeNewswire
Virtu Financial LLC Has $59,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Acadian Asset Management LLC Takes $56,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $2.00 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Two Hundred Day Moving Average of $2.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $2.01 - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected - Simply Wall St
ProQR Therapeutics - The Pharma Letter
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):